NCT00132912 is a Phase 2 clinical trial of SCH 530348 in Arterial Obstructive Diseases, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT00132912?

NCT00132912 is sponsored by Merck Sharp & Dohme LLC.

What drugs are being tested in NCT00132912?

Interventions in NCT00132912: SCH 530348.

What condition does NCT00132912 study?

NCT00132912 studies Arterial Obstructive Diseases, Coronary Disease.

Is NCT00132912 still recruiting?

NCT00132912 is currently completed. Last updated 25 May 2017.

Last reviewed 2017-05-25 · How we verify

NCT00132912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

Completed Phase 2 Last updated 25 May 2017

What this trial tests

Phase 2 trial testing SCH 530348 in Arterial Obstructive Diseases in 1,030 participants. Completed in 28 January 2007.

Timeline

30 August 2005

Primary endpoint
28 January 2007

28 January 2007

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	1,030
Start date	30 August 2005
Primary completion	28 January 2007
Estimated completion	28 January 2007

Drugs / interventions tested

SCH 530348 — full drug profile →

Conditions studied

Arterial Obstructive Diseases — all drugs for Arterial Obstructive Diseases →
Coronary Disease — all drugs for Coronary Disease →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

45 and older, any sex, with Arterial Obstructive Diseases or Coronary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding. A secondary objective is to determine whether patients treated with SCH 530348 have fewer cardiac events such as heart attack, bypass surgery, or death compared with those persons treated with the standard of care.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.
Becker RC, Moliterno DJ, Jennings LK, Pieper KS, et al · · 2009 · cited 212× · PMID 19286091 · DOI 10.1016/s0140-6736(09)60230-0
Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention?
Chambers RC. · · 2008 · cited 123× · PMID 18223674 · DOI 10.1038/sj.bjp.0707603
Targeting PAR1: Now What?
Flaumenhaft R, De Ceunynck K. · · 2017 · cited 73× · PMID 28558960 · DOI 10.1016/j.tips.2017.05.001

Verify or expand the search:

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00132912 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 25 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00132912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing